BR0114392A - Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv - Google Patents
Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsvInfo
- Publication number
- BR0114392A BR0114392A BR0114392-1A BR0114392A BR0114392A BR 0114392 A BR0114392 A BR 0114392A BR 0114392 A BR0114392 A BR 0114392A BR 0114392 A BR0114392 A BR 0114392A
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine formulation
- vaccine
- rsv
- intranasal
- suffering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18563—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18661—Methods of inactivation or attenuation
- C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"FORMULAçãO DE VACINA, MéTODO PARA PRODUZIR UMA FORMULAçãO DE VACINA, USO DE UMA PREPARAçãO DE VACINA CONTRA RSV DIVIDIDO, KIT PARA LIBERAçãO DE UMA FORMULAçãO DE VACINA INTRANASAL, DISPOSITIVO DE LIBERAçãO INTRANASAL, E, MéTODO PARA PROTEGER OU TRATAR UM MAMìFERO SUSCEPTìVEL A, OU SOFRENDO DE DOENçA CAUSADA POR RSV". A invenção refere-se a formulações de vacina compreendendo uma preparação de vírus envelopado, em que o vírus é RSV ou PIV, métodos para preparar as formulações, e uso das formulações na prevenção ou tratamento de doença.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0024088A GB0024088D0 (en) | 2000-10-02 | 2000-10-02 | Novel compounds |
GB0109288A GB0109288D0 (en) | 2001-04-12 | 2001-04-12 | Novel compounds |
PCT/EP2001/011328 WO2002028426A1 (en) | 2000-10-02 | 2001-10-01 | Split enveloped virus preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114392A true BR0114392A (pt) | 2003-09-02 |
Family
ID=26245086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114392-1A BR0114392A (pt) | 2000-10-02 | 2001-10-01 | Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040028698A1 (pt) |
EP (1) | EP1322329A1 (pt) |
JP (1) | JP2004510747A (pt) |
KR (1) | KR20030055275A (pt) |
CN (1) | CN1253207C (pt) |
AR (1) | AR030829A1 (pt) |
AU (2) | AU1591402A (pt) |
BR (1) | BR0114392A (pt) |
CA (1) | CA2423610A1 (pt) |
CZ (1) | CZ2003930A3 (pt) |
HU (1) | HUP0302636A3 (pt) |
IL (1) | IL155073A0 (pt) |
MX (1) | MXPA03002890A (pt) |
NO (1) | NO20031484L (pt) |
NZ (1) | NZ525076A (pt) |
PL (1) | PL362964A1 (pt) |
WO (1) | WO2002028426A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2244946C (en) * | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
MXPA03002890A (es) * | 2000-10-02 | 2004-12-03 | Glaxosmithkline Biolog Sa | Preparacion de virus con envolvente dividido. |
TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
CN1305526C (zh) * | 2003-12-29 | 2007-03-21 | 薛平 | 乙型脑炎病毒裂解疫苗及其制备方法 |
JP2008531581A (ja) * | 2005-02-23 | 2008-08-14 | ユーエービー リサーチ ファウンデーション | アルキル−グリコシドで増強されたワクチン接種 |
WO2007015441A1 (ja) | 2005-08-01 | 2007-02-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよび製剤 |
AU2007209104B2 (en) * | 2006-01-26 | 2010-04-08 | Zoetis Services Llc | Novel glycolipid adjuvant compositions |
GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
JP5275047B2 (ja) * | 2007-01-31 | 2013-08-28 | 久光製薬株式会社 | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
AU2009333484B2 (en) | 2008-12-09 | 2014-12-11 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US20130236496A1 (en) * | 2010-06-29 | 2013-09-12 | Universite De Laval | Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response |
EA201391515A1 (ru) * | 2011-05-26 | 2014-05-30 | Глаксосмитклайн Байлоджикалс С.А. | Инактивированная вакцина вируса денге |
WO2015064710A1 (ja) | 2013-10-31 | 2015-05-07 | 久光製薬株式会社 | アジュバント組成物、これを含むアジュバント製剤、及びキット |
US20160287693A1 (en) | 2013-11-15 | 2016-10-06 | Novartis Ag | Removal of residual cell culture impurities |
FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
CN108697790B (zh) | 2015-09-03 | 2022-02-18 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
AU2019238171A1 (en) | 2018-03-19 | 2020-09-24 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
US11576960B2 (en) | 2018-03-30 | 2023-02-14 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (RSV) vaccines |
CN110665002B (zh) * | 2019-10-29 | 2023-01-24 | 信阳市动物疫病预防控制中心 | 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法 |
CN113804593B (zh) * | 2020-06-11 | 2024-05-24 | 北京科兴生物制品有限公司 | 一种裂解疫苗裂解效果的检测方法及应用 |
WO2022003565A1 (en) * | 2020-07-01 | 2022-01-06 | Medimmune, Llc | Detergent and method for purifying a biotherapeutic |
CN112190705A (zh) * | 2020-09-25 | 2021-01-08 | 广州源博医药科技有限公司 | 一种rsv-sh亚单位疫苗及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1486557A (en) * | 1973-10-18 | 1977-09-21 | Flockhart & Co | Process for the preparation of pyrogen-free sub-unit vaccine |
DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
BR9909915A (pt) * | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
JP2003531866A (ja) * | 2000-05-03 | 2003-10-28 | メディミューン,インコーポレイテッド | 抗体を用いた呼吸器疾患の組合せ治療法 |
MXPA03002890A (es) * | 2000-10-02 | 2004-12-03 | Glaxosmithkline Biolog Sa | Preparacion de virus con envolvente dividido. |
-
2001
- 2001-10-01 MX MXPA03002890A patent/MXPA03002890A/es unknown
- 2001-10-01 EP EP01986267A patent/EP1322329A1/en not_active Withdrawn
- 2001-10-01 CZ CZ2003930A patent/CZ2003930A3/cs unknown
- 2001-10-01 AU AU1591402A patent/AU1591402A/xx active Pending
- 2001-10-01 HU HU0302636A patent/HUP0302636A3/hu unknown
- 2001-10-01 NZ NZ525076A patent/NZ525076A/en unknown
- 2001-10-01 JP JP2002532250A patent/JP2004510747A/ja active Pending
- 2001-10-01 BR BR0114392-1A patent/BR0114392A/pt not_active Application Discontinuation
- 2001-10-01 KR KR10-2003-7004718A patent/KR20030055275A/ko not_active Application Discontinuation
- 2001-10-01 AU AU2002215914A patent/AU2002215914B2/en not_active Ceased
- 2001-10-01 PL PL01362964A patent/PL362964A1/xx unknown
- 2001-10-01 IL IL15507301A patent/IL155073A0/xx unknown
- 2001-10-01 AR ARP010104630A patent/AR030829A1/es unknown
- 2001-10-01 US US10/381,486 patent/US20040028698A1/en not_active Abandoned
- 2001-10-01 CA CA002423610A patent/CA2423610A1/en not_active Abandoned
- 2001-10-01 WO PCT/EP2001/011328 patent/WO2002028426A1/en not_active Application Discontinuation
- 2001-10-01 CN CNB018198090A patent/CN1253207C/zh not_active Expired - Fee Related
-
2003
- 2003-04-01 NO NO20031484A patent/NO20031484L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20031484L (no) | 2003-05-28 |
KR20030055275A (ko) | 2003-07-02 |
HUP0302636A3 (en) | 2008-03-28 |
NZ525076A (en) | 2004-09-24 |
CN1253207C (zh) | 2006-04-26 |
AU1591402A (en) | 2002-04-15 |
JP2004510747A (ja) | 2004-04-08 |
EP1322329A1 (en) | 2003-07-02 |
CA2423610A1 (en) | 2002-04-11 |
PL362964A1 (en) | 2004-11-02 |
AU2002215914B2 (en) | 2004-08-19 |
HUP0302636A2 (hu) | 2003-11-28 |
NO20031484D0 (no) | 2003-04-01 |
CZ2003930A3 (cs) | 2003-08-13 |
US20040028698A1 (en) | 2004-02-12 |
AR030829A1 (es) | 2003-09-03 |
WO2002028426A8 (en) | 2002-06-06 |
CN1477973A (zh) | 2004-02-25 |
IL155073A0 (en) | 2003-10-31 |
WO2002028426A1 (en) | 2002-04-11 |
MXPA03002890A (es) | 2004-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0114392A (pt) | Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv | |
BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
CY1109929T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της | |
BR0213358A (pt) | Uso de flibanserina | |
BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
BR0111358A (pt) | Compostos de tioacetamida e seu uso | |
BRPI0407950A (pt) | processo para a preparação de uma composição de higiene pessoal | |
BR9916694A (pt) | Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal | |
BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
ES2162319T3 (es) | Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer. | |
BR0010531A (pt) | Composições e usos de et743 para tratamento de câncer | |
PT1024824E (pt) | Composicao de vacina dispersivel solida para administracao oral | |
EP1074245A3 (en) | Composition using mineral salts for therapeutic treatment | |
CO5090882A1 (es) | Nueva vacuna y procedimiento de uso des transmitidas sexualmente | |
BR0101486A (pt) | Composições farmacêuticas de uso tópico, aplicadas no tratamento de lesões de pele e/ou mucosas; uso das composições no tratamento de lesões de pele e/ou mucosas e uso de compostos no tratamento de lesões de pele e/ou mucosas | |
BR0109716A (pt) | Uso de um nucleosìdeo ou um análogo de nucleosìdeo no tratamento de infecção viral por hepatite delta | |
BR0110971A (pt) | Composições e métodos para tratamento de infecções das mucosas | |
BR0107960A (pt) | Tratamento de condições alérgicas e inflamatórias | |
BR0114933A (pt) | Uso de uma alga marinha ascophyllum sp. ou um extrato desta, dose unitária de uma preparação oral, e, método profilático e/ou terapêutico de tratamento de placa e/ou cálculo em um indivìduo mamìfero em necessidade do mesmo | |
NZ505538A (en) | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma | |
BR0009194A (pt) | Composição do resorcinol | |
BR0109770A (pt) | Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer | |
BR9106166A (pt) | Uso de cetorolac para o tratamento de doenca periodontal | |
BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |